Published in Lancet on December 07, 1996
FLEX - Long-term Extension of FIT (Fracture Intervention Trial)(0217-051) | NCT00398931
Selling sickness: the pharmaceutical industry and disease mongering. BMJ (2002) 10.98
2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ (2002) 9.89
Osteoporosis: now and the future. Lancet (2011) 5.81
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2008) 5.27
Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int (2014) 5.17
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2012) 4.88
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int (2008) 4.73
Computer-aided diagnosis in medical imaging: historical review, current status and future potential. Comput Med Imaging Graph (2007) 4.23
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 4.15
Changing perceptions in osteoporosis. BMJ (1999) 3.30
Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women. Ann Intern Med (2011) 2.96
Low-energy distal radius fractures in middle-aged and elderly men and women--the burden of osteoporosis and fracture risk : A study of 1794 consecutive patients. Osteoporos Int (2009) 2.77
Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc (2008) 2.66
Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int (2006) 2.34
A longitudinal HR-pQCT study of alendronate treatment in postmenopausal women with low bone density: Relations among density, cortical and trabecular microarchitecture, biomechanics, and bone turnover. J Bone Miner Res (2010) 2.32
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract (2011) 2.29
Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab (2010) 2.29
Fracture risk following an osteoporotic fracture. Osteoporos Int (2003) 2.21
Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid. JAMA Intern Med (2014) 2.20
The fracture liaison service: success of a program for the evaluation and management of patients with osteoporotic fracture. Osteoporos Int (2003) 2.19
Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study. Osteoporos Int (2015) 2.15
Advances in osteoporosis therapy. 2003 update of practical guidelines. Can Fam Physician (2003) 2.09
Validation of a short questionnaire for estimating dietary calcium intakes. Osteoporos Int (2014) 2.06
Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis. Osteoporos Int (2013) 2.05
Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int (2003) 2.02
Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data. BMJ (2009) 2.00
Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract (2012) 1.84
Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int (2010) 1.83
Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. British Society of Gastroenterology. Gut (2000) 1.81
Healing delayed but generally reliable after bisphosphonate-associated complete femur fractures treated with IM nails. Clin Orthop Relat Res (2014) 1.78
Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab (2010) 1.77
Osteoporosis and its management. BMJ (2006) 1.75
Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. JAMA Intern Med (2014) 1.75
Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest (1998) 1.75
Effects of risedronate and low-dose transdermal testosterone on bone mineral density in women with anorexia nervosa: a randomized, placebo-controlled study. J Clin Endocrinol Metab (2011) 1.74
Clinical risk factors as predictors of postmenopausal osteoporosis in general practice. Br J Gen Pract (2001) 1.73
Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int (2003) 1.72
Should we look for osteoporosis in patients with rheumatoid arthritis? Ann Rheum Dis (1998) 1.72
The relationship between bisphosphonate adherence and fracture: is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial. J Bone Miner Res (2011) 1.70
Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int (2010) 1.69
Inadequate responders to osteoporosis treatment: proposal for an operational definition. Osteoporos Int (2008) 1.68
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis (2005) 1.66
Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int (2008) 1.65
A comparison of parathyroid hormone-related protein (1-36) and parathyroid hormone (1-34) on markers of bone turnover and bone density in postmenopausal women: the PrOP study. J Bone Miner Res (2013) 1.65
Extraintestinal manifestations of inflammatory bowel disease. J Pediatr Gastroenterol Nutr (2008) 1.64
Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop (2009) 1.64
Bone regenerative medicine: classic options, novel strategies, and future directions. J Orthop Surg Res (2014) 1.64
Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician (2014) 1.63
Capture the Fracture: a Best Practice Framework and global campaign to break the fragility fracture cycle. Osteoporos Int (2013) 1.60
Sacral insufficiency fractures: current concepts of management. Osteoporos Int (2006) 1.58
Preventing fractures in elderly people. BMJ (2003) 1.57
Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int (2006) 1.56
Case reports: two femoral insufficiency fractures after long-term alendronate therapy. Clin Orthop Relat Res (2009) 1.55
Effect of whole body vibration (WBV) therapy on bone density and bone quality in osteopenic girls with adolescent idiopathic scoliosis: a randomized, controlled trial. Osteoporos Int (2012) 1.53
Absolute risk reduction in osteoporosis: assessing treatment efficacy by number needed to treat. Rheumatol Int (2009) 1.53
The management of osteoporosis following hip fracture: have we improved our care? Osteoporos Int (2003) 1.52
Spectroscopic markers of bone quality in alendronate-treated postmenopausal women. Osteoporos Int (2008) 1.52
The role of DXA bone density scans in the diagnosis and treatment of osteoporosis. Postgrad Med J (2007) 1.51
Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int (2011) 1.50
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res (2016) 1.50
Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial. Lancet Oncol (2014) 1.48
Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int (2004) 1.48
Epidemiology and direct medical costs of osteoporotic fractures in men and women in Switzerland. Osteoporos Int (2004) 1.48
Conventional treatments for ankylosing spondylitis. Ann Rheum Dis (2002) 1.48
Shear strength and toughness of trabecular bone are more sensitive to density than damage. J Biomech (2011) 1.48
Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity. Bone (2009) 1.47
Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ (2000) 1.47
Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra. Osteoporos Int (2007) 1.47
Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res (2008) 1.47
Recognition of osteoporosis by primary care physicians. Am J Public Health (2002) 1.46
Identification and validation of vertebral compression fractures using administrative claims data. Med Care (2009) 1.45
Build better bones with exercise: protocol for a feasibility study of a multicenter randomized controlled trial of 12 months of home exercise in women with a vertebral fracture. Phys Ther (2014) 1.44
The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr Clin Pharmacol (2013) 1.44
The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab (2005) 1.43
New targets for intervention in the treatment of postmenopausal osteoporosis. Nat Rev Rheumatol (2011) 1.43
Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark. Osteoporos Int (2004) 1.43
Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study. J Bone Miner Res (2005) 1.42
Effect of dosing interval duration of intermittent ibandronate treatment on the healing process of femoral osteotomy in a rat fracture model. Calcif Tissue Int (2012) 1.41
Which screening strategy using BMD measurements would be most cost effective for hip fracture prevention in elderly women? A decision analysis based on a Markov model. Osteoporos Int (2006) 1.41
UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos (2017) 1.40
The vertebral fracture cascade in osteoporosis: a review of aetiopathogenesis. Osteoporos Int (2007) 1.40
Ten-year fracture probability identifies women who will benefit from clodronate therapy--additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int (2008) 1.39
Esophageal irritation due to alendronate sodium tablets: possible mechanisms. Dig Dis Sci (1998) 1.39
Detection, evaluation, and treatment of eating disorders the role of the primary care physician. J Gen Intern Med (2000) 1.37
Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos Int (2005) 1.36
Therapeutic effects of alendronate 35 mg once weekly and 5 mg once daily in Japanese patients with osteoporosis: a double-blind, randomized study. J Bone Miner Metab (2005) 1.34
Refractures in cemented vertebrae after percutaneous vertebroplasty: a retrospective analysis. Eur Spine J (2008) 1.33
Canadian Consensus Conference on osteoporosis, 2006 update. J Obstet Gynaecol Can (2006) 1.33
Fracture risk is increased in Crohn's disease, but not in ulcerative colitis. Gut (2000) 1.33
Declining incidence of hip fractures and the extent of use of anti-osteoporotic therapy in Denmark 1997-2006. Osteoporos Int (2009) 1.33
Assessment of prevalent and incident vertebral fractures in osteoporosis research. Osteoporos Int (2003) 1.33
Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial. Osteoporos Int (2014) 1.29
Incidence and risk factors for a second hip fracture in elderly women. The Study of Osteoporotic Fractures. Osteoporos Int (2003) 1.28
Osteoporosis, frailty and fracture: implications for case finding and therapy. Nat Rev Rheumatol (2012) 1.28
The assessment of fracture risk. J Bone Joint Surg Am (2010) 1.27
Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogs. J Bone Miner Res (2010) 1.25
Prevalent vertebral fractures in black women and white women. J Bone Miner Res (2008) 1.25
Bisphosphonates in the management of postmenopausal osteoporosis--optimizing efficacy in clinical practice. Clin Interv Aging (2008) 1.22
Patient treatment preferences for osteoporosis. Arthritis Rheum (2006) 1.22
Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc (2000) 39.79
Physical activity and public health. A recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA (1995) 38.40
Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res (1987) 24.27
Compendium of physical activities: classification of energy costs of human physical activities. Med Sci Sports Exerc (1993) 19.40
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med (2001) 16.81
Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med (1995) 13.01
Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med (1992) 12.89
Unruptured intracranial aneurysms: natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet (2003) 11.91
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA (1999) 11.23
Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med (2000) 11.12
Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res (1993) 10.98
Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet (1993) 9.34
Whole-Organ Magnetic Resonance Imaging Score (WORMS) of the knee in osteoarthritis. Osteoarthritis Cartilage (2004) 8.50
CHAMPS physical activity questionnaire for older adults: outcomes for interventions. Med Sci Sports Exerc (2001) 7.96
Physical activity assessment methodology in the Five-City Project. Am J Epidemiol (1985) 7.90
Effects of communitywide education on cardiovascular disease risk factors. The Stanford Five-City Project. JAMA (1990) 7.44
Epidemiology of osteoporosis and osteoporotic fractures. Epidemiol Rev (1985) 7.40
A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med (1997) 7.11
Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med (2001) 6.76
Community education for cardiovascular health. Lancet (1977) 6.32
Appendicular bone density and age predict hip fracture in women. The Study of Osteoporotic Fractures Research Group. JAMA (1990) 6.25
Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst (2003) 6.20
Assessment of habitual physical activity by a seven-day recall in a community survey and controlled experiments. Am J Epidemiol (1985) 6.10
Risk factors for recurrent nonsyncopal falls. A prospective study. JAMA (1989) 5.93
Accurate assessment of precision errors: how to measure the reproducibility of bone densitometry techniques. Osteoporos Int (1995) 5.22
The International Cooperative Study on the Timing of Aneurysm Surgery. Part 1: Overall management results. J Neurosurg (1990) 4.72
Why are African Americans under-represented in medical research studies? Impediments to participation. Ethn Health (1997) 4.63
Forgetting falls. The limited accuracy of recall of falls in the elderly. J Am Geriatr Soc (1988) 4.61
Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med (1999) 4.53
Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med (1999) 4.45
Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med (1990) 4.10
Health risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study. Osteoporos Int (2012) 4.09
The Stanford Five-City Project: design and methods. Am J Epidemiol (1985) 4.06
Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc (2000) 4.05
Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab (2001) 4.03
Measuring higher level physical function in well-functioning older adults: expanding familiar approaches in the Health ABC study. J Gerontol A Biol Sci Med Sci (2001) 4.01
Comparison of fixed-flexion positioning with fluoroscopic semi-flexed positioning for quantifying radiographic joint-space width in the knee: test-retest reproducibility. Skeletal Radiol (2003) 3.93
Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. N Engl J Med (1998) 3.86
Continuing screening mammography in women aged 70 to 79 years: impact on life expectancy and cost-effectiveness. JAMA (1999) 3.82
Risk factors for injurious falls: a prospective study. J Gerontol (1991) 3.79
Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med (1990) 3.76
Risk of mortality following clinical fractures. Osteoporos Int (2000) 3.76
Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab (2000) 3.68
Type of fall and risk of hip and wrist fractures: the study of osteoporotic fractures. The Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc (1993) 3.55
Peak bone mass. Osteoporos Int (2000) 3.49
Measuring fitness in healthy older adults: the Health ABC Long Distance Corridor Walk. J Am Geriatr Soc (2001) 3.39
Patterns of cognitive decline in presymptomatic Alzheimer disease: a prospective community study. Arch Gen Psychiatry (2001) 3.32
Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med (1993) 3.23
Moderate-intensity exercise and self-rated quality of sleep in older adults. A randomized controlled trial. JAMA (1997) 3.23
The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med (1998) 3.13
New approaches for interpreting projected bone densitometry data. J Bone Miner Res (1992) 3.12
Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res (1999) 3.08
Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med (1998) 3.05
Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int (2011) 3.04
Bone mineral acquisition in healthy Asian, Hispanic, black, and Caucasian youth: a longitudinal study. J Clin Endocrinol Metab (1999) 3.03
Percutaneous injuries during surgical procedures. JAMA (1992) 3.01
Comparison of two methods of assessing physical activity in the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Am J Epidemiol (1991) 2.96
Indirect measures of cigarette use: expired-air carbon monoxide versus plasma thiocyanate. Prev Med (1984) 2.91
Physical performance measures in aging research. J Gerontol (1989) 2.86
Physical fitness as a predictor of cardiovascular mortality in asymptomatic North American men. The Lipid Research Clinics Mortality Follow-up Study. N Engl J Med (1988) 2.84
Lifetime cost of stroke in the United States. Stroke (1996) 2.83
Smoking, alcohol, and neuromuscular and physical function of older women. Study of Osteoporotic Fractures Research Group. JAMA (1994) 2.82
Enhancing community participation in intervention research: farmworkers and agricultural chemicals in North Carolina. Health Educ Behav (1999) 2.82
Contribution of vertebral deformities to chronic back pain and disability. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res (1992) 2.82
Cognitive decline in women in relation to non-protein-bound oestradiol concentrations. Lancet (2000) 2.82
Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of Osteoporotic Fractures Research Group. Arch Intern Med (2000) 2.81
Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. Fracture Intervention Trial Research Group. J Am Geriatr Soc (2000) 2.80
Cognitive tests that best discriminate between presymptomatic AD and those who remain nondemented. Neurology (2000) 2.79
Simple measurement of femoral geometry predicts hip fracture: the study of osteoporotic fractures. J Bone Miner Res (1993) 2.78
Physical activity and the prevention of coronary heart disease. Ann Clin Res (1971) 2.77
A high ratio of dietary animal to vegetable protein increases the rate of bone loss and the risk of fracture in postmenopausal women. Study of Osteoporotic Fractures Research Group. Am J Clin Nutr (2001) 2.76